Search our Database of Scientific Publications and Authors

I’m looking for a

    3598 results match your criteria Oral Malignant Melanoma

    1 OF 72

    Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Department of Dermatology, Dermatologist, Hospital Universitario Doctor Peset, Valencia, Spain.
    Vemurafenib ha probado ser una herramienta útil en el tratamiento de melanoma metastásico con mutación BRAF-V600E. Los efectos adversos incluyen artralgias, fatiga y toxicidad cutánea, siendo infrecuente la paniculitis. Presentamos el caso de una paciente de 43 años con melanoma metastásico que desarrolla lesiones subcutáneas dolorosas en miembros inferiores y superiores, asociadas a clínica sistémica después de 2 semanas de inicio de tratamiento con Vemurafenib + Cobimetinib. Read More

    Lichen planus: molecular pathway and clinical implications in oral disorders.
    J Biol Regul Homeost Agents 2018 Jan-Feb;32(2 Suppl. 1):135-138
    Department of Biochemistry, Biophysics and General Pathology, University of Campania “Luigi Vanvitelli”, Naples, Italy.
    Stem cells play a role in many mucosal disorders characterised by abnormal proliferation and differentiation of keratinocytes, such as oral lichen planus (OLP). In OLP there were changes in stem cell markers as component of integrin complexes α6 and β1 integrin increased along with increase of melanoma-associated chondroitin sulphate proteoglycan (MCSP) and decreased of notch1 (N1) and keratin 15 (K15). Stem cell marker expression may be altered by pathological signalling in these lesions. Read More

    Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma: A Case Report.
    Intern Med 2018 Feb 9. Epub 2018 Feb 9.
    Department of Gastroenterology, Toyonaka Municipal Hospital, Japan.
    A 42-year-old man was diagnosed with cStage IIIb malignant melanoma and underwent resection. After interferon-beta therapy, 18-fluorodeoxyglucose-positron emission tomography/computed tomography (F-FDG PET/CT) showed multiple lung metastases, and he received nivolumab (2 mg/kg) every 3 weeks, resulting in a total of 17 cycles. After treatment,F-FDG PET/CT showed a significant decrease in the size of the metastases, but he had a Grade 4 ALT elevation. Read More

    Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    J Immunother Cancer 2018 Feb 12;6(1):13. Epub 2018 Feb 12.
    Hematology/Oncology, Norris cotton Cancer Center, One Medical Center Dr., Lebanon, NH, 03756, USA.
    Background: Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e. Read More

    Longitudinal clinicopathologic data of the progression of oral mucosal melanoma-report of 2 cases and literature review.
    Oral Surg Oral Med Oral Pathol Oral Radiol 2017 Dec 28. Epub 2017 Dec 28.
    Diagnostic Sciences, TAMU College of Dentistry, Dallas, TX, USA.
    Oral mucosal melanoma (OMM) is notorious for having a poor prognosis. Recognition of the early features of OMM by both clinicians and pathologists can play an important role in improving survival. Therefore, the purpose of this report is to increase awareness of the early features of OMM, by presenting 2 cases with longitudinal clinical and histopathologic documentation showing progression of OMM from a deceptively bland premalignant (noninvasive) oral melanocytic lesion (POML). Read More

    Second Malignancies after Hematopoietic Stem Cell Transplantation.
    Curr Treat Options Oncol 2018 Feb 8;19(2). Epub 2018 Feb 8.
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    Opinion Statement: Second malignancies are a rare but well-defined late complication after autologous and allogeneic hematopoietic stem-cell transplantation (SCT). Solid malignancies occur in up to 15% of patients 15 years after SCT with myeloablative conditioning, with no plateau in the incidence rates. They are responsible for 5-10% of late deaths after SCT. Read More

    Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling.
    J Clin Exp Dent 2017 Dec 1;9(12):e1492-e1495. Epub 2017 Dec 1.
    DDS, MSc, PhD, Professor, Department of Oral Medicine and Pathology, Faculty of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
    Sinonasal mucosal melanoma is a rare tumor that develops slowly and may manifest with non specific signs and symptoms, causing significant delay in diagnosis. Local recurrence is common and usually occurs within the first two years after the initial treatment. Prognosis of recurrent lesions is poor and 5-year survival ranges between 10-47%. Read More

    Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
    Cell Immunol 2018 Jan 30. Epub 2018 Jan 30.
    Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy. Electronic address:
    In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Read More

    Photocarcinogenesis and Skin Cancer Prevention Strategies: An Update.
    Anticancer Res 2018 02;38(2):1153-1158
    Clinic and Polyclinic for Dermatology and Venerology, University Medical Center Rostock, Rostock, Germany
    UV radiation is acknowledged as the primary cause of photocarcinogenesis and therefore contributes to the development of skin cancer entities such as squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and melanoma. Typical DNA photoproducts and indirect DNA damage caused by reactive oxygen species are the result of UV radiation. UV-induced DNA damage is repaired by nucleotide excision repair, which consequently counteracts the development of mutations and skin carcinogenesis. Read More

    Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Lancet Oncol 2018 Feb 18;19(2):181-193. Epub 2018 Jan 18.
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
    Background: Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. Read More

    Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    J Dermatol 2018 Jan 20. Epub 2018 Jan 20.
    Department of Dermatology, Kitasato University School of Medicine, Kanagawa, Japan.
    Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment opinion for advanced melanoma and non-small-cell lung cancer, as well as other cancerous entities. Immune checkpoint inhibitors such as anti-PD-1 antibody result in a unique side-effect profile, commonly described as immune-related adverse events (irAE). These irAE affect the skin, gastrointestinal tract, liver, endocrine system and other organ systems. Read More

    Cytologic Features of Malignant Melanoma with Osteoclast-Like Giant Cells.
    Acta Cytol 2018 Jan 13. Epub 2018 Jan 13.
    Department of Pathology, University Hospital La Princesa, Madrid, Spain.
    Background: Malignant melanoma showing numerous osteoclast-like giant cells (OGCs) is an uncommon morphologic phenomenon, rarely mentioned in the cytologic literature. The few reported cases seem to have an aggressive clinical behavior. Although most findings support monocyte/macrophage differentiation, the exact nature of OGCs is not clear. Read More

    FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
    Retina 2018 Jan 10. Epub 2018 Jan 10.
    Department of Ophthalmology, Scheie Eye Institute at the Perelman Center for Advanced Medicine, the.
    Purpose: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma.

    Methods: Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31-68 years of age) were included. Treatment was with oral dabrafenib, 150 mg bid, trametinib, 2 mg/day, and HCQ, 400 mg to 600 mg bid. Read More

    Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.
    Bioorg Med Chem 2018 02 20;26(3):581-589. Epub 2017 Dec 20.
    Shanghai Hengrui Pharmaceutical Co. Ltd., 279 Wenjing Rd, Minhang Hi-tech Zone, Shanghai 200245, China.
    A novel series of benzodihydrofuran derivatives was developed as potent MEK inhibitors through scaffold hopping based on known clinical compounds. Further SAR exploration and optimization led to another benzofuran series with good oral bioavailability in rats. One of the compounds EBI-1051 (28d) demonstrated excellent in vivo efficacy in colo-205 tumor xenograft models in mouse and is suitable for pre-clinical development studies for the treatment of melanoma and MEK associated cancers. Read More

    Improving anti-melanoma effect of curcumin by biodegradable nanoparticles.
    Oncotarget 2017 Dec 24;8(65):108624-108642. Epub 2017 Aug 24.
    Department of Pathology, West China Second university Hospital, Sichuan University, Chengdu, PR China.
    Melanoma is known as the most common malignant cutaneous cancer. Curcumin, a natural component, has been shown to have various activities such as anti-oxidant, anti-septic, anti-inflammatory, anti-biotic, anti-amyloid and anti-thrombosis. However, there is a greatest obstacle in the administration of curcumin due to its hydrophobicity and low oral bioavailability. Read More

    A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis.
    Case Rep Med 2017 22;2017:1093858. Epub 2017 Oct 22.
    Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
    We report an 81-year-old man with multiple liver metastases after tumorectomy for primary mediastinal malignant melanoma, who experienced limb weakness and sensory disturbance after nivolumab monotherapy. He was diagnosed with nivolumab-induced mononeuropathy multiplex and rhabdomyolysis based on serologic examination, muscle biopsy, magnetic resonance imaging of the limbs, and a nerve conduction study. A course of intravenous methylprednisolone (mPSL) was initiated at 1 g/day for 3 days. Read More

    Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer.
    J Craniomaxillofac Surg 2018 Mar 24;46(3):492-497. Epub 2017 Dec 24.
    Department of Oral and Maxillofacial Plastic Surgery, Head: Alexander C. Kübler, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
    Melanoma-associated antigen A (MAGE-A) proteins are members of the cancer/testis antigens (CTA), and the expression of these proteins is almost exclusively limited to malignant cells, making them an attractive treatment target. MAGE-A expression is correlated with poor overall survival in several cancers, including head and neck squamous cell carcinoma (HNSCC). Among others, MAGE-A11 was found to be associated with resistance to different antineoplastic and targeted compounds, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Read More

    Eosinophils: The unsung heroes in cancer?
    Oncoimmunology 2018 13;7(2):e1393134. Epub 2017 Nov 13.
    Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
    Prolonged low-grade inflammation or smoldering inflammation is a hallmark of a cancer. Eosinophils are components of the immune microenvironment that modulates tumor initiation and progression. Although canonically associated with a detrimental role in allergic disorders, these cells can induce a protective immune response against helminthes, viral and bacterial pathogens. Read More

    Pigmented Squamous Cell Carcinoma In Situ: Report of a New Case and Review of the Literature.
    J Clin Exp Dent 2017 Nov 1;9(11):e1362-e1365. Epub 2017 Nov 1.
    MDS, DDS, Division of General Pathology, Department of Stomatology, School of Dentistry, University of São Paulo, Sao Paulo, SP, Brazil.
    Pigmented squamous cell carcinoma in situ (PSCCIS) is very rare, being clinically described as a pigmented lesion with histological characteristics of an in-situ carcinoma presenting pigmentation within neoplastic cells. A 50-year-old Afro-descendant man came for clinical evaluation of a painful black and red lesion located on the right aspect of the oropharyngeal isthmus. After incisional biopsy, the resulting sample was described as a pigmented squamous cell carcinoma in situ, a diagnosis further confirmed by immunohistochemical analysis. Read More

    KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro.
    Cancer Lett 2018 Mar 18;417:75-88. Epub 2017 Dec 18.
    Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, 119991, Russia. Electronic address:
    KISS1 tumor suppressor protein regulates cancer cell invasion via MMP9 metalloproteinase. Downregulation of KISS1 gene expression promotes progression of breast cancer and melanoma, resulting in the development of distant metastases. In the current study, we investigated whether restoration of KISS1 expression in KISS1-deficient human metastatic breast cancer cells holds potential as an advanced anticancer strategy. Read More

    Unexpected discovery of small HNF1α-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours.
    Liver Int 2017 Dec 19. Epub 2017 Dec 19.
    Inserm, UMR1053 Bordeaux Research In Translational Oncology, BaRITOn, Université de Bordeaux, Bordeaux, France.
    Background And Aims: It is rare but not uncommon to discover micro/small HNF1α-inactivated hepatocellular adenoma (H-HCA) outside the context of resected H-HCA. We aimed to review our cases of micro/small H-HCA discovered by chance on different kinds of liver resected specimens.

    Methods: We retrieved cases of micro/small H-HCA discovered by chance on resected specimens outside the context of H-HCA. Read More

    RSAD2 and AIM2 modulate CV-A16 and EV-A71 replication in neuronal cells in different ways that may be associated with their 5' non-translated regions.
    J Virol 2017 Dec 20. Epub 2017 Dec 20.
    Departments of Pathology and Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    Coxsackievirus A16 (CV-A16) and Enterovirus A71 (EV-A71) are closely related enteroviruses that cause the same hand, foot and mouth disease but neurological complications occur only very rarely in CV-A16 compared to EV-A71 infections. To elucidate host responses that may be able to explain these differences, we performed transcriptomic analysis and qRT-PCR in CV-A16 infected neuroblastoma cells (SK-N-SH) which showed that the radical s-adenosyl methionine domain containing 2 (RSAD2) was the highest up-regulated gene in the anti-microbial pathway. Increased RSAD2 expression was correlated with reduced viral replication while RSAD2 knockdown cells were correlated with increased replication. Read More

    Epidemiology of basal cell carcinoma: a 10-year comparative study.
    Br J Oral Maxillofac Surg 2018 Feb 15;56(2):101-106. Epub 2017 Dec 15.
    Division of Oral and Maxillofacial Surgery, Poole Hospital NHS Foundation Trust, United Kingdom.
    Basal cell carcinoma (BCC) is a slow-growing and locally aggressive skin cancer. Despite its high incidence, good quality epidemiological data are sparse. We therefore organised a retrospective study of two separate years' incidence of BCC in one county within the United Kingdom (Dorset) with an interval of 10 years between them. Read More

    A preliminary immunohistochemical study of signal transducer and activator of transcription (STAT) proteins in primary oral malignant melanoma.
    Oral Surg Oral Med Oral Pathol Oral Radiol 2018 Feb 3;125(2):164-171. Epub 2017 Nov 3.
    Department of Oral Medicine and Pathology, Dental School, National and Kapodistrian University of Athens, Greece.
    Objective: Primary oral malignant melanoma (POMM) is a rare type of malignancy with a very poor prognosis, the molecular pathogenesis of which remains elusive. The aim of this study was to assess the expression status of signal transducer and activator of transcription (STAT) proteins in POMM.

    Study Design: Six POMMs were included in the study. Read More

    [What's new in instrumental dermatology?]
    Ann Dermatol Venereol 2017 Dec;144 Suppl 4:IVS10-IVS15
    Service de dermatologie générale et oncologique, CHU Ambroise-Paré 9, avenue Charles-de-Gaulle, 92200 Boulogne-Billancourt, 75007 Paris, France; cabinet médical, 4 bis, avenue de Ségur, 75007 Paris, France. Electronic address:
    This "What's new in instrumental dermatology" dedicated skin surgeryis based upon a 2015-2017 literature analysis. The excision of skin cancers is an important part of surgical dermatology. Will artificial intelligence and new drug be able to face the increasing need for therapy? Wrong-site surgery is due to multiple factors. Read More

    Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile.
    Amino Acids 2018 Feb 12;50(2):267-278. Epub 2017 Dec 12.
    Departamento do Farmacologia, Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM), Rua 3 de maio 100, Ed. INFAR, 3rd Floor, São Paulo, CEP 04044-020, Brazil.
    The efficacy of crotamine as antitumoral was first demonstrated by daily intraperitoneal (IP) injections of low doses of this toxin in an animal model bearing melanoma tumors. Significant inhibition of tumor growth and increased lifespan of mice bearing tumor was also noticed after 21 consecutive days of this daily IP administration of crotamine. However, due to the limited acceptance of treatments by IP route in clinical conditions, herein, we evaluated the antitumor effect of this native polypeptide employing the oral route. Read More

    Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
    J Pathol 2018 Mar 5;244(3):358-366. Epub 2018 Feb 5.
    Bio-X Institutes, Ministry of Education Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Institute of Social Cognitive and Behavioral Sciences, Shanghai Jiao Tong University, Shanghai, PR China.
    Oral mucosal melanoma (OMM) is a rare and aggressive subtype of melanoma with little known about its pathogenesis or carcinogenesis. We therefore performed whole-exome sequencing (WES) on 19 matched OMM tumor/normal pairs in order to gain insight into potential genetic drivers of tumor formation. For the first time, we describe the comprehensive mutational profile of OMM. Read More

    Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features.
    J Am Acad Dermatol 2017 Dec 9. Epub 2017 Dec 9.
    Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Melanoma differentiation-associated gene 5 (MDA5) is a recently described autoantigen target in a subset of patients with dermatomyositis. Anti-MDA5 dermatomyositis is characterized by a unique mucocutaneous and systemic phenotype that includes cutaneous and oral ulceration, painful palmar papules, alopecia, panniculitis, arthritis, a lower incidence of myositis, and, importantly, an elevated risk of interstitial lung disease with a potentially fatal course. Because the clinical features can differ substantially from those typically observed in cutaneous dermatomyositis, the diagnosis is often overlooked, which might negatively affect patient outcomes. Read More

    EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.
    Oncotarget 2017 Nov 8;8(56):95412-95424. Epub 2017 Sep 8.
    Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.
    Melanoma is the most biologically aggressive skin cancer of well established constitutive and induced resistance to pharmacological treatment. Despite the recent progresses in immunotherapies, many advanced metastatic melanoma patients still face a significant mortality risk. The aggressive nature of this disease sustains an urgent need for more successful, effective drugs. Read More

    Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".
    Ann Oncol 2017 Dec 5. Epub 2017 Dec 5.
    Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Italy.
    Background: Alveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS.

    Patients And Methods: Eligible patients with reference pathology-confirmed ASPS received oral crizotinib 250 mg twice daily. Read More

    The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.
    Molecules 2017 Dec 7;22(12). Epub 2017 Dec 7.
    Department of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warsaw, Poland.
    Background: Cancer remains a leading cause of death in companion animals. In human medicine, liposomes and nanoparticles have been extensively investigated as drug delivery systems (DDS) for anticancer agents due to their ability to target cancerous cells and reduce the negative side effects of free cytostatic drugs. In this review, the authors discuss the results of clinical trials using liposomes and polymer-based nanoparticles as DDS to improve cancer treatment in dogs and cats, indicating which ones seem worth further evaluation. Read More

    In vivo intraoral reflectance confocal microscopy of an amalgam tattoo.
    Dermatol Pract Concept 2017 Oct 31;7(4):13-16. Epub 2017 Oct 31.
    Dermatology Service, Memorial Sloan Kettering Cancer Center, Hauppauge, NY, USA.
    The majority of oral pigmentations are benign lesions such as nevi, melanotic macules, melanoacanthomas or amalgam tattoos. Conversely, mucosal melanomas are rare but often lethal; therefore, excluding oral melanomas in this setting is crucial. Reflectance confocal microscopy is a non-invasive, in vivo imaging system with cellular resolution that has been used to distinguish benign from malignant pigmented lesions in the skin, and more recently in the mucosa. Read More

    Hypo-fractionated Radiation, Magnetic Nanoparticle Hyperthermia and a Viral Immunotherapy Treatment of Spontaneous Canine Cancer.
    Proc SPIE Int Soc Opt Eng 2017 Jan-Feb;10066. Epub 2017 Feb 22.
    Geisel School of Medicine, Dartmouth College 1 Rope Ferry Road, Hanover, NH, USA 03755.
    It has recently been shown that cancer treatments such as radiation and hyperthermia, which have conventionally been viewed to have modest immune based anti-cancer effects, may, if used appropriately stimulate a significant and potentially effective local and systemic anti-cancer immune effect (abscopal effect) and improved prognosis. Using eight spontaneous canine cancers (2 oral melanoma, 3 oral amelioblastomas and 1 carcinomas), we have shown that hypofractionated radiation (6 x 6 Gy) and/or magnetic nanoparticle hyperthermia (2 X 43°C / 45 minutes) and/or an immunogenic virus-like nanoparticle (VLP, 2 x 200 μg) are capable of delivering a highly effective cancer treatment that includes an immunogenic component. Two tumors received all three therapeutic modalities, one tumor received radiation and hyperthermia, two tumors received radiation and VLP, and three tumors received only mNP hyperthermia. Read More

    [Actinomycosis revealed by ulceration of the palate and gingiva].
    Ann Dermatol Venereol 2017 Nov 28. Epub 2017 Nov 28.
    Service de dermatologie, CHU d'Amiens, 1, place Victor-Pauchet, 80000 Amiens, France; Université de Picardie-Jules-Verne, 80000 Amiens, France.
    Background: Actinomycosis is a chronic and extensive granulomatous, bacterial infection. Revelation by oral ulceration is rare.

    Patients And Methods: A 76-year-old patient with diabetes was treated with dabrafenib for stage IV melanoma. Read More

    Bilateral uveitis and macular edema induced by Nivolumab: a case report.
    BMC Ophthalmol 2017 Dec 1;17(1):227. Epub 2017 Dec 1.
    Department of Dermatology, Service de dermatologie, ImmuCare, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand revoyet, Pierre Bénite Cedex, France.
    Background: Nivolumab is a fully human antibody which is routinely used at first therapy for metastatic melanoma. Usually, side effects are immune-related adverse events. We report a case of a man who developed bilateral anterior uveitis and macular serous retinal detachment during nivolumab treatment for metastatic melanoma. Read More

    A hot-water extract of Sanguisorba officinalis ameliorates endotoxin-induced septic shock by inhibiting inflammasome activation.
    Microbiol Immunol 2018 Jan;62(1):44-54
    Division of Biotechnology, College of Environmental and Bioresources, Chonbuk National University, Iksan-si, Jeollabuk-do 570-752, South Korea.
    The inflammasome is a multiprotein signaling complex that mediates inflammatory innate immune responses through caspase 1 activation and subsequent IL-1β secretion. However, because its aberrant activation often leads to inflammatory diseases, targeting the inflammasome holds promise for the treatment of inflammation-related diseases. In this study, it was found that a hot-water extract of Sanguisorba officinalis (HSO) suppresses inflammasome activation triggered by adenosine 5'-triphosphate, nigericin, microbial pathogens, and double stranded DNA in bone marrow-derived macrophages. Read More

    A preliminary investigation of the effect of sample collection technique on the cell and RNA content of fine-needle aspirates of five canine tumours.
    J Small Anim Pract 2017 Nov 29. Epub 2017 Nov 29.
    Department of Molecular Oncology, Animal Health Trust, Newmarket, Suffolk, CB7 5UU, UK.
    Objectives: To evaluate the effect of syringe size, needle size, number of needle passes and operator experience on cell yield from tumour fine-needle aspirates, and the quantity and quality of extractable RNA.

    Materials And Methods: Fine-needle aspirates were collected from canine lymphoma, cutaneous mast cell tumour, anal gland adenocarcinoma, fibrosarcoma and oral malignant melanoma using nine different techniques.

    Results: There was a significant difference in cell yield between fine-needle aspirate techniques for melanoma, lymphoma and anal gland adenocarcinoma. Read More

    Nicotinamide and skin cancer chemoprevention: The jury is still out.
    Australas J Dermatol 2018 Feb 28;59(1):6-9. Epub 2017 Nov 28.
    Skin and Cancer Foundation, Melbourne, Victoria, Australia.
    Following the publication of the results of a Phase III trial, the administration of oral nicotinamide has been widely advocated as effective in non-melanoma skin cancer chemoprevention in high-risk individuals. However, I performed a Bayesian analysis of the reported findings and show there is insufficient evidence to demonstrate its efficacy, highlighting the significant probability that the positive conclusions drawn will not be reproducible. Given the potential widespread use of oral nicotinamide, future position statements regarding its efficacy are likely to require higher standards of evidence. Read More

    Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
    Cell Cycle 2017 Nov 29:1-22. Epub 2017 Nov 29.
    a AntiCancer , Inc. , San Diego , CA.
    The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated by intra-peritoneal injection (ip-rMETase), could inhibit tumor growth in a patient-derived orthotopic xenograft (PDOX) model of a BRAF-V600E mutant melanoma. Read More

    Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.
    Oncotarget 2017 Oct 26;8(51):89182-89193. Epub 2017 Sep 26.
    Department of Hematology, Oncology and Blood and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
    Introduction: Epigenetic modifications play an important role in progression and development of resistance inBRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA methyltransferase inhibitor). The primary objective of this phase lb study was to determine the dose limiting toxicity and maximum tolerated dose of combination of subcutaneous decitabine with oral vemurafenib in patients withBRAF positive metastatic melanoma with or without any prior treatment. Read More

    Are patients satisfied with the head and neck skin cancer service? An evaluation of outpatient services with a review of published reports.
    Br J Oral Maxillofac Surg 2017 Dec 21;55(10):1018-1023. Epub 2017 Nov 21.
    Department of Oral & Maxillofacial Surgery, Northampton General Hospital, Northampton, NN1 5BD. Electronic address:
    Scientific publications place much emphasis on postoperative outcomes such as recurrence, but little attention to patients' satisfaction. The purpose of this evaluation was to find out patients' reported outcomes after their initial consultation, treatment, and follow-up appointments for non-melanoma skin cancer of the head and neck. We used an adapted version of the European Organisation for Research and Treatment of Cancer (EORTC) validated questionnaire for patients' satisfaction to collect data prospectively from consenting patients between September and December 2015. Read More

    Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.
    Oncologist 2017 Nov 20. Epub 2017 Nov 20.
    Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
    Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. Read More

    Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Oncotarget 2017 Oct 12;8(49):85516-85525. Epub 2017 Aug 12.
    AntiCancer, Inc., San Diego, CA, USA.
    An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant methioninase (rMETase). The present study used a previously-established patient-derived orthotopic xenograft (PDOX) nude mouse model of BRAF V600E-mutant melanoma to determine the efficacy of rMETase in combination with a first-line melanoma drug, temozolomide (TEM). Read More

    P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Pharmacol Res 2017 Nov 14. Epub 2017 Nov 14.
    The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address:
    Encorafenib (LGX818) is a promising BRAFinhibitor that has efficacy against metastatic melanoma. To better understand its pharmacokinetics, we studied its interactions with the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug metabolizing enzyme CYP3A. In polarized MDCK-II cells, encorafenib was efficiently transported by canine and human ABCB1 and ABCG2 and by mouse Abcg2. Read More

    Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases.
    J Cancer 2017 17;8(18):3828-3837. Epub 2017 Oct 17.
    Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200011, China.
    To investigate the relationship between clinical and histopathological characteristics and overall survival of patients with oral mucosal melanoma (OMM) without distal metastasis in order to provide predictive prognostic information of OMM.Ki67 expression was assessed by immunohistochemistry in 123 patients with OMM without distant metastases. The associations between Ki67 expression and clinical features and overall survival (OS) of patients were statistically analyzed. Read More

    Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Eur J Cancer 2017 12 14;87:147-163. Epub 2017 Nov 14.
    Gustave Roussy, Department of Medical Oncology, Villejuif, France.
    Purpose: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-).

    Experimental Design: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Read More

    1 OF 72